Streetbeat News

Earnings

BAC

Bank of America's Q3 consumer banking revenue was $10.5 billion, up 6% from the previous quarter. However, average deposits were down 8% to $980 billion. Net income was $2.9 billion, and average loans and leases increased by 5% to $311 billion. Combined credit/debit card spend was $225 billion, up 3%.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 10:47 am

BAC

Bank of America's Q3 provision for credit losses has increased by $336M to $1.2B.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 10:46 am

BAC

Bank of America (NYSE:BAC) reported Q3 earnings of $0.90 per share, beating the analyst consensus estimate of $0.81 by 11.11%. This is a 11.11% increase over earnings of $0.81 per share from the same period last year. The bank's Q3 revenue, net of interest expense, was $25.2B, up 3%.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 10:46 am

BAC

Bank of America has reported its Q3 earnings per share (EPS) at $0.90.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 10:44 am

BK

Bank of New York Mellon (BK) reported Q3 total revenue of $4.40B, beating the estimate of $4.33B. The bank also saw a 10% increase in net interest revenue.

Portfolio Pulse from Bill Haddad

October 17, 2023 | 10:36 am

BK

Bank of New York Mellon (NYSE:BK) reported Q3 earnings of $1.27 per share, beating the analyst consensus estimate of $1.15 by 10.43 percent. This represents a 4.96 percent increase over earnings of $1.21 per share from the same period last year.

Portfolio Pulse from Bill Haddad

October 17, 2023 | 10:35 am

GMAB

Genmab A/S (NASDAQ:GMAB) announced Q3 net sales of $2.5B for DARZALEX (daratumumab), including sales of the subcutaneous product sold under the tradename DARZALEX FASPRO in the U.S. The sales were reported by Johnson & Johnson, with $1.37B in the U.S. and $1.13B in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX under the exclusive worldwide license to Janssen.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 10:29 am

JNJ

Johnson & Johnson has revised its FY23 adjusted EPS forecast to $10.07-$10.13, up from the previous range of $10.00-$10.10. This new estimate surpasses the consensus of $10.03.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 10:29 am

JNJ

Johnson & Johnson has updated its FY23 sales forecast to a range of $83.6B-$84.0B, up from the previous range of $83.2B-$84.0B. However, this is still below the consensus estimate of $84.53B.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 10:27 am

AMAM

EDIT

ERIC

NOK

NTCT

OBDC

SPWR

Several stocks including NetScout Systems, Ambrx Biopharma, Ericsson, SunPower Corporation, Nokia, Editas Medicine, and Blue Owl Capital Corporation recorded losses in Tuesday's pre-market trading session. NetScout Systems reported weak preliminary results for Q2 and lowered its FY24 guidance, causing its shares to dip 23%. Ambrx Biopharma's shares declined after announcing updated safety and efficacy data from an ongoing trial. Ericsson reported downbeat Q3 sales, leading to a fall in its shares.

Portfolio Pulse from Lisa Levin

October 17, 2023 | 10:25 am